Tag : endpoint

Latest News

Aliqopa™ (copanlisib) in Combination With Rituximab Meets Primary Endpoint in Patients With Relapsed Indolent Non-Hodgkin’s Lymphoma

Newsemia
WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer announced today that the Phase III study CHRONOS-3 evaluating Aliqopa™ (copanlisib) in combination with rituximab in indolent Non-Hodgkin’s Lymphoma (iNHL) patients (n=458)...
AI/ML

CCAE: Cross-field categorical attributes embedding for cancer clinical endpoint prediction.

Newsemia
CCAE: Cross-field categorical attributes embedding for cancer clinical endpoint prediction. Artif Intell Med. 2020 Jul;107:101915 Authors: Li Y, Zhu Z, Wu H, Ding S, Zhao...
Latest News

Genentech’s Tecentriq in Combination With Chemotherapy (including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People With Early Triple-negative Breast Cancer

Newsemia
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpassion031 study, evaluating...
Latest News

Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death Source link...
Neurology

SUNFISH: Risdiplam Meets Primary Endpoint in SMA

Newsemia
Risdiplam, an oral investigational agent designed to increase and sustain SMN protein levels of patients with spinal muscular atrophy (SMA), met the primary endpoint in...
Latest News

IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Newsemia
NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. announced initial topline data confirming that Zimura® met its prespecified primary endpoint in its Phase 2b clinical trial. Source link...
Latest News

Pivotal RESTORE-IMI 2 Phase 3 Study of Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Pivotal RESTORE-IMI 2 Phase 3 Study of Merck’s RECARBRIO™ in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Met Primary Endpoint Source link...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy